Phathom Pharmaceuticals Marks GERD Awareness Week 2026 by Urging Americans to Take Frequent Heartburn Seriously
Phathom Pharmaceuticals is observing GERD Awareness Week 2026 by encouraging Americans to take frequent heartburn seriously, as it could be a sign of gastroesophageal reflux disease (GERD). The company released a "Holiday Heartburn Myths vs. Facts" infographic and continues its #GERDtoKnow social media education series to highlight the prevalence and potential complications of GERD. Phathom aims to raise awareness and urge individuals with persistent symptoms to consult their healthcare providers for proper diagnosis and treatment.
Phathom Pharmaceuticals' Robert Breedlove to Resign as Finance VP
Robert Breedlove, Vice President of Finance and principal accounting officer at Phathom Pharmaceuticals (PHAT), will resign effective December 4, 2026. The company stated that his resignation is not due to any disagreement with their operations, policies, or practices, and replacement information has not been disclosed. This announcement is based on an SEC Form 8-K filing from November 18, 2026.
PHAT: Phathom Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
Phathom Pharmaceuticals Inc. (PHAT) filed an SEC Form 8-K announcing that Robert Breedlove, the Vice President, Finance and principal accounting officer, will resign effective December 4, 2026. The filing explicitly states that his departure is not due to any disagreement with the company's operations, policies, or practices, presenting it as a routine staffing change. While the company will need to find a replacement for this senior finance role, the filing suggests no underlying disputes.
Clients hold the 30,562 shares Invesco reports in Phathom Pharmaceuticals (PHAT).
Invesco Ltd. has reported beneficial ownership of 30,562 shares of Phathom Pharmaceuticals, Inc. (PHAT) as of September 30, 2026. These shares are held of record by Invesco clients, with no single person having more than 5% economic ownership. Invesco maintains sole voting power over 30,223 shares and sole dispositive power over all 30,562 shares.
Phathom Pharmaceuticals, Inc. (PHAT) stock price, news, quote and history
Phathom Pharmaceuticals, Inc. (PHAT) is a biopharmaceutical company focused on treatments for gastrointestinal diseases, including VOQUEZNA for GERD and Helicobacter pylori. The company's stock is currently trading at $5.59, down 1.58%, with a market capitalization of $454.42 million. Analyst estimates place a 1-year target price of $20.05, and recent performance shows a 66.31% YTD return for PHAT.
Phathom Pharmaceuticals to present at three major healthcare investor conferences in November 2026
Phathom Pharmaceuticals announced its management team will participate in three major healthcare investor conferences in November 2026, including Guggenheim Healthcare Innovation, Stifel Healthcare, and Jefferies Global Healthcare. These events will feature fireside chats and one-on-one meetings to discuss the company's progress, particularly concerning its gastrointestinal disease treatment VOQUEZNA. The article also provides a brief market snapshot for the healthcare sector, noting the performance of several US health-sector stocks.
What Phathom Pharmaceuticals Bears Spotted Before A 63% Slide
Phathom Pharmaceuticals experienced a 63% slide in its stock price in 2026 despite Q3 results showing higher revenue and a smaller loss. Investors are weighing two narratives: a bullish view based on significant revenue growth and profit margin swing, and a bearish one focusing on regulatory hurdles and high spending potentially hindering profitability. The company's VOQUEZNA drug is a key factor, with new data suggesting cost-effectiveness, but execution risks and access hurdles remain concerns for its future growth.
Phathom Pharmaceuticals to Participate in November Investor Conferences
Phathom Pharmaceuticals, Inc. announced its management team will participate in three investor conferences in November 2026: the Guggenheim 3rd Annual Healthcare Innovation Conference, the Stifel 2026 Healthcare Conference, and the Jefferies Global Healthcare Conference. Management will hold fireside chats and one-on-one meetings at each event. The company, focused on GI disease treatments, will also provide access to live webcasts and archived recordings of these events on its investor relations website.
Phathom management has talks scheduled in Boston, New York and London.
Phathom Pharmaceuticals (Nasdaq: PHAT) is scheduled to participate in three investor conferences in November 2026. Management will hold fireside chats and one-on-one meetings at Guggenheim in Boston on November 10, Stifel in New York on November 11, and Jefferies in London on November 18. The company will discuss its focus on commercializing and developing novel treatments for gastrointestinal diseases, including its flagship product, VOQUEZNA.
Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx
Phathom Pharmaceuticals has partnered with BlinkRx to allow eligible commercially insured patients to pay as little as $0 for VOQUEZNA® (vonoprazan) tablets, a treatment for gastroesophageal reflux disease (GERD). This initiative aims to improve access and affordability, offering free home delivery and support with insurance requirements like prior authorizations. Additionally, options are available for commercially insured patients who prefer retail pharmacies and a cash-pay option for uninsured patients.
Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx
Phathom Pharmaceuticals announced that eligible commercially insured patients can now pay as little as $0 for VOQUEZNA® (vonoprazan) tablets exclusively through BlinkRx. This initiative aims to improve accessibility and affordability for GERD patients by offering free home delivery, prior authorization support, and automatic identification of the lowest out-of-pocket cost. The program is part of Phathom's commitment to ensuring patients can easily start and stay on their prescribed medication.
How Phathom Pharmaceuticals Inc. (PHAT) Affects Rotational Strategy Timing
Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) is showing weak sentiment across all horizons, supporting a short bias according to AI models. The analysis identifies a mid-channel oscillation pattern and an exceptional 81.0:1 risk-reward setup. Three distinct trading strategies are proposed, including position, momentum breakout, and risk hedging, each with specific entry, target, and stop-loss parameters.
Form 13D/A PHATHOM PHARMACEUTICALS For: 2 November By Investing.com
This article announces the filing of a Form 13D/A for PHATHOM PHARMACEUTICALS, dated November 2nd. The filing is a disclosure statement required by the SEC when a person or group acquires beneficial ownership of more than 5% of a company's voting class of equity securities.
Form 13D/A PHATHOM PHARMACEUTICALS For: 2 November By Investing.com
This article announces the filing of Form 13D/A for PHATHOM PHARMACEUTICALS on November 2, 2026. The brief piece indicates that this financial disclosure is available from Investing.com, a platform that provides financial market information.
Phathom Pharmaceuticals (PHAT) Stock Price, Chart & Analysis
This article provides a detailed analysis of Phathom Pharmaceuticals (PHAT) stock, including its latest price, market capitalization, and key financial figures. It also offers insights into its valuation, growth, margins, and debt, as well as a "Belegger score" based on Buffett and Lynch metrics. The report concludes with various hypothetical scenarios for future price performance.
H.C. Wainwright reiterates Buy on Phathom stock, $26 target
H.C. Wainwright has reiterated a Buy rating and a $26 price target for Phathom Pharmaceuticals (NASDAQ:PHAT), noting the stock's current trading price of $6.22 offers significant upside. The firm highlighted Phathom's commercial strategy execution in GI conditions, including erosive GERD and non-erosive NERD, as well as its progress with the vonoprazan pipeline. Phathom recently announced positive regulatory developments regarding VOQUEZNA's exclusivity and reported strong third-quarter 2026 financial results, surpassing EPS expectations.
Phathom Pharmaceuticals (NASDAQ:PHAT) Reports 71% Revenue Growth in Q3 2026
Phathom Pharmaceuticals (NASDAQ:PHAT) announced a 71% year-over-year revenue increase to $84.7 million in Q3 2026, driven by strong commercial performance of its GERD treatment, VOQUEZNA. The company achieved positive operating cash flow for the second consecutive quarter and reaffirmed its full-year 2026 financial guidance. Phathom is also advancing its pipeline with the initiation of a Phase 3 study for VOQUEZNA in Non-Erosive Gastroesophageal Reflux Disease (NERD).
What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call
Phathom Pharmaceuticals reported strong Q3 2026 financial results, including significant revenue growth and positive operating profit, driven by the expansion of its GERD treatment, VOQUEZNA. The company is actively working to reduce prescribing barriers and improve patient affordability through its "Access First" strategy, which includes a $0 copay offering via BlinkRx. Phathom maintained its full-year 2026 revenue guidance and is progressing with clinical trials for VOQUEZNA in eosinophilic esophagitis and as-needed non-erosive GERD, while also defending its regulatory exclusivity in ongoing litigation.
Phathom Pharmaceuticals Reports Q3 2026 Revenue of $84.7M with Reduced Net Loss
Phathom Pharmaceuticals (NASDAQ: PHAT) reported a significant increase in Q3 2026 net product revenue to $84.7 million, up from $49.5 million in Q3 2025. The company also reduced its net loss to $13.9 million in Q3 2026, compared to $29.9 million in the prior-year period. For the first nine months of 2026, net product revenue reached $217.3 million, and the net loss narrowed to $61.8 million.
Phathom Pharmaceuticals Q3 2026 Earnings Call Transcript
Phathom Pharmaceuticals reported a significant 71% year-over-year increase in net revenues for Q3 2026, reaching $84.7 million, and achieved its second consecutive quarter of positive operating profit excluding stock-based compensation. The company maintained its full-year revenue guidance and is actively implementing "Access First" initiatives to improve physician prescribing and patient access to Voquezna, including a new $0 copay offering through BlinkRx. Phathom is also progressing with development programs for EoE and non-erosive GERD, while vigorously defending Voquezna's exclusivity period amidst ongoing litigation.
Phathom Pharmaceuticals, Inc. (PHAT) Tops Q3 EPS by 14c
Phathom Pharmaceuticals, Inc. (PHAT) announced Q3 EPS of $0.04, exceeding analyst estimates by $0.14. The company reported quarterly revenue of $84.7 million, slightly below the consensus estimate of $85.51 million. Following the announcement, PHAT's stock price was $5.92, down 5.73%.
Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue Estimates
Phathom Pharmaceuticals (PHAT) reported Q3 earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.07, though this was an improvement from a $0.15 loss a year ago. The company's revenues for the quarter were $84.72 million, also falling short of the Zacks Consensus Estimate by 1.71%. Despite mixed estimate revisions ahead of the report, the stock currently holds a Zacks Rank #3 (Hold).
Phathom Pharmaceuticals Posts $84.7 Million Revenue, $3.0 Million Adjusted Net Income
Phathom Pharmaceuticals reported strong third-quarter 2026 results, with net revenue climbing 71% year over year to $84.7 million and achieving a non-GAAP adjusted net income of $3.0 million. The company reaffirmed its full-year 2026 financial guidance, anticipating net revenue between $310 million and $325 million. Business highlights include over 2 million VOQUEZNA prescriptions filled and progress in its Phase 3 and Phase 2 studies for GERD and EoE, respectively.
Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Phathom Pharmaceuticals reported strong third-quarter 2026 financial results, with net revenues reaching $84.7 million, a 71% increase year-over-year. The company achieved positive operating cash flow for the second consecutive quarter and reaffirmed its full-year 2026 financial guidance. Key commercial progress includes over two million VOQUEZNA prescriptions filled and the initiation of a Phase 3 study for as-needed use in Non-Erosive GERD.
Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
Phathom Pharmaceuticals (Nasdaq: PHAT) reported strong third-quarter 2026 financial results, with net revenues of $84.7 million, a 71% increase year-over-year. The company also announced over 2 million total VOQUEZNA® prescriptions filled and reaffirmed its full-year 2026 financial guidance. Phathom is advancing its clinical programs for VOQUEZNA, including a Phase 3 study for as-needed use in Non-Erosive GERD and expects Phase 2 results for Eosinophilic Esophagitis (EoE) in Q4 2026.
Form 8K Phathom Pharmaceuticals Inc For: 26 October By Investing.com
Phathom Pharmaceuticals Inc. filed a Form 8K for October 26, as reported by Investing.com. This filing is a significant event for shareholders and market observers, indicating a material event or corporate change for the company. The article mentions a current stock increase of 3.51% for Phathom Pharmaceuticals (PHAT).
Phathom Pharmaceuticals: FDA Opens Comment Docket on VOQUEZNA Exclusivity Challenge
The FDA has opened a public docket regarding legal and regulatory questions concerning a challenge to VOQUEZNA’s NCE exclusivity, which extends through May 3, 2032. This action follows BDR's litigation challenging the FDA's rejection of its ANDA referencing VOQUEZNA. Phathom Pharmaceuticals announced it will submit comments supporting the FDA's original exclusivity decision, while a second filer, Saba, intends to seek consolidation of its related pending case with BDR’s litigation.
Comments on the FDA’s VOQUEZNA docket close November 23, 2026, Phathom (PHAT) says.
Phathom Pharmaceuticals (PHAT) announced that the FDA has opened a public comment period regarding legal and regulatory questions surrounding its drug VOQUEZNA, prompted by a lawsuit from BDR Pharmaceuticals. Comments on the docket (FDA-2026-N-13038) are due by November 23, 2026. Phathom maintains that its VOQUEZNA holds 10 years of New Chemical Entity (NCE) exclusivity through May 3, 2032, a decision supported by the FDA in June 2025.
Phathom Faces FDA Review of VOQUEZNA 2032 Exclusivity
Phathom Pharmaceuticals is facing an FDA review of the exclusivity for its drug VOQUEZNA, following a legal challenge by BDR Pharmaceuticals. The FDA has opened a public docket to gather comments on the legal and regulatory questions surrounding VOQUEZNA's 10-year New Chemical Entity exclusivity, which Phathom believes extends until May 3, 2032. Phathom intends to defend its exclusivity rights through public comments to the FDA and by intervening in BDR's ongoing lawsuit, which could impact the timing of generic competition.
Phathom Pharmaceuticals Provides Update on FDA Litigation
Phathom Pharmaceuticals announced that the FDA has established a public docket to gather comments on legal and regulatory questions regarding litigation brought by BDR Pharmaceuticals, an ANDA filer, against the FDA. This litigation challenges the FDA's decision to grant Phathom 10 years of New Chemical Entity (NCE) exclusivity for VOQUEZNA until May 3, 2032. Phathom intends to intervene in the litigation and submit comments to the public docket to defend its statutory exclusivities for VOQUEZNA.
Phathom Pharmaceuticals Provides Update on FDA Litigation
Phathom Pharmaceuticals announced that the FDA has established a public docket to solicit comments on legal and regulatory questions regarding an abbreviated new drug application (ANDA) referencing its drug VOQUEZNA. This follows litigation brought against the FDA challenging its decision to grant Phathom's Citizen Petition, which affirmed VOQUEZNA's 10-year New Chemical Entity (NCE) exclusivity through May 3, 2032. Phathom intends to intervene in the litigation and submit comments to the FDA to protect its statutory exclusivities.
Phathom Pharmaceuticals, Inc. Estimates – NASDAQ:PHAT
This page on TradingView provides financial data and analyst estimates for Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT). Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with average, high, and low estimates, and visualizing trends over time. The platform explicitly states that the content is not investment advice and encourages users to conduct their own research.
Phathom Pharmaceuticals (PHAT) Shares Drop 18% Amid FDA Lawsuit Over Voquezna Generic Application
Phathom Pharmaceuticals (PHAT) saw its stock price drop by 18% after BDR Pharmaceuticals International Pvt. Ltd. filed a lawsuit against the FDA, challenging the agency's refusal to accept a generic drug application for Phathom's product, Voquezna. The lawsuit disputes the FDA's application of the GAIN Act exclusivity provisions, which currently protect Voquezna until May 3, 2032. This legal battle and Phathom's weak financial fundamentals, including ongoing losses and a low GF Score, have led to cautious sentiment among investors and analysts.
Phathom Pharmaceuticals reports lawsuit over Voquezna exclusivity
Phathom Pharmaceuticals announced a lawsuit filed by BDR Pharmaceuticals International Pvt. Ltd. against the FDA, challenging the agency's alleged refusal to accept an abbreviated new drug application (ANDA) referencing Phathom’s VOQUEZNA. BDR argues that the FDA improperly extended Phathom's New Chemical Entity (NCE) exclusivity for VOQUEZNA through May 3, 2032. Phathom stated its intention to take appropriate action to protect its statutory exclusivities.
Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
Phathom Pharmaceuticals announced that BDR Pharmaceuticals International Pvt. Ltd. has filed a lawsuit against the FDA, challenging the FDA's application of the GAIN Act which granted Phathom 10 years of New Chemical Entity (NCE) exclusivity for its drug VOQUEZNA® (vonoprazan fumarate) tablets until May 3, 2032. Phathom believes the FDA correctly evaluated the issue and intends to take appropriate action to protect its statutory exclusivities. The litigation concerns the FDA's alleged refusal to receive an abbreviated new drug application (ANDA) referencing Phathom's NDA for VOQUEZNA®.
Form 8K Phathom Pharmaceuticals Inc For: 23 October By Investing.com
This article from Investing.com announces that Phathom Pharmaceuticals Inc. filed a Form 8K on October 23, 2026. The Form 8K is a crucial SEC filing used by public companies to announce major events that shareholders should know about. The article provides the title of the filing and its publication details.
Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Cuts Target Price to $15
Craig-Hallum has reiterated its Buy rating on Phathom Pharmaceuticals (PHAT.US) but has adjusted its price target downwards from $20 to $15. This adjustment reflects a revised outlook on the company's valuation while maintaining a positive sentiment on its future prospects.
Phathom schedules October 29 results. Jefferies sets USD 16 target for Phathom Pharmaceuticals stock
Phathom Pharmaceuticals has scheduled its third-quarter results webcast for October 29, 2026, at 8:00 a.m. EDT. Jefferies recently lowered its price target for Phathom stock from USD 20.00 to USD 16.00, while maintaining a Buy rating. The company also announced three scientific presentations related to VOQUEZNA and highlighted cost-effectiveness data.
Phathom Pharmaceuticals, Inc. (PHAT) Stock Price, News, Quote & History
Phathom Pharmaceuticals, Inc. (PHAT) stock closed at $7.01, showing a slight decrease after hours. The company, focused on gastrointestinal disease treatments, has a market cap of $567.116M and an average analyst target of $19.64. Recent performance indicates significant year-to-date and 1-year declines, but a 5-year return that outperforms the S&P 500.
At 8 a.m. Oct. 29, Phathom's results webcast begins; a recording will be available for 90 days.
Phathom Pharmaceuticals (PHAT) announced it will report its third-quarter 2026 financial results and provide a business update on Thursday, October 29, 2026. Management will host a live webcast at 8:00 am EDT, accessible via the company's website, with a recording available for 90 days afterward. The company, focused on gastrointestinal diseases, markets vonoprazan-based treatments like VOQUEZNA for GERD and H. pylori infection.
Phathom Pharmaceuticals to Host Third Quarter 2026 Financial Results Webcast on October 29
Phathom Pharmaceuticals announced it will host a live webcast on October 29, 2026, at 8:00 am EDT to discuss its third-quarter 2026 financial results and provide a business update. The company focuses on developing and commercializing treatments for gastrointestinal diseases, notably marketing vonoprazan under the brand name VOQUEZNA® in the U.S. The webcast will be available on their website, with a recording accessible for 90 days.
Phathom Pharmaceuticals to Report Third Quarter 2026
Phathom Pharmaceuticals, Inc. announced it will report its third quarter 2026 financial results and provide a business update on Thursday, October 29, 2026, at 8:00 am EDT. The company, focused on gastrointestinal diseases, will host a live webcast accessible via its investor relations website. A recording will be available for 90 days following the event.
Jefferies cuts Phathom Pharmaceuticals price target on 2027 outlook
Jefferies has lowered its price target for Phathom Pharmaceuticals (NASDAQ:PHAT) to $16 from $20, while maintaining a Buy rating, due to a challenging year for the stock, which has fallen 58% year-to-date. Despite past logistical issues, the firm views the 2027 outlook favorably, especially with an anticipated competitor PDUFA decision, believing that two products in the market will increase awareness. Phathom recently reported strong Q2 2026 revenue growth and is initiating a Phase 3 trial for VOQUEZNA, even as it adjusted full-year guidance due to prior authorization challenges.
Behavioral Patterns of PHAT and Institutional Flows
This article provides an AI-driven analysis of Phathom Pharmaceuticals Inc. (NASDAQ: PHAT), highlighting a near-term strong sentiment that challenges persistent mid and long-term weakness. It identifies an 81.5:1 risk-reward setup targeting a 25.2% gain against a 0.3% risk, along with specific institutional trading strategies (Position, Momentum Breakout, and Risk Hedging) and multi-timeframe signal analysis. The report also details current signal strengths and support/resistance levels for various time horizons.
Phathom Pharmaceuticals Highlights New Cost-Effectiveness
Phathom Pharmaceuticals presented new cost-effectiveness data and clinical insights for its drug VOQUEZNA (vonoprazan) at the ACG 2026 Annual Scientific Meeting. A new analysis suggests VOQUEZNA is cost-effective compared to proton pump inhibitors for treating Erosive GERD, potentially offering healthcare savings due to fewer long-term complications. Additionally, the company highlighted VOQUEZNA's efficacy across various BMI subgroups in Non-Erosive GERD and noted significant independent research interest in vonoprazan for multiple gastrointestinal conditions.
Form 4 Phathom Pharmaceuticals Inc For: 8 October By Investing.com
This article announces the filing of a Form 4 for Phathom Pharmaceuticals Inc., dated October 8. It indicates that the company's stock, PHAT, saw a 4.70% increase. The piece provides no further details about the Form 4 content itself, serving primarily as a brief notification.
Form 4 Phathom Pharmaceuticals Inc For: 8 October By Investing.com
This article from Investing.com reports on a Form 4 filing for Phathom Pharmaceuticals Inc. dated October 8. It indicates a news publication date of October 08, 2026, at 06:16 p.m. and includes the company's stock symbol PHAT with a 4.70% gain.
Phathom to present VOQUEZNA data at gastroenterology meeting
Phathom Pharmaceuticals Inc. will present three scientific posters on its drug VOQUEZNA (vonoprazan) at the American College of Gastroenterology Annual Scientific Meeting. The presentations will cover VOQUEZNA's efficacy in Non-Erosive GERD across BMI subgroups, real-world patient characteristics, and a cost-effectiveness analysis compared to proton pump inhibitors in Erosive Esophagitis. Key researchers from Yale and UNC Schools of Medicine will present these findings, and the company will also host a product theater.
For tax withholding, Phathom (PHAT) CFO surrenders 13,485 shares at $6.78 each.
Sanjeev Narula, the Chief Financial & Bus. Officer of Phathom Pharmaceuticals (PHAT), surrendered 13,485 shares of common stock on October 6, 2026, at a price of $6.78 per share. This transaction was to fulfill the issuer's tax-withholding obligation. After the surrender, Narula's direct holdings amount to 214,718 shares and indirect holdings through a 401(k) are 1,123 shares.
Phathom to present VOQUEZNA data at gastroenterology meeting By Investing.com
Phathom Pharmaceuticals (NASDAQ: PHAT) is scheduled to present three scientific posters on its drug VOQUEZNA at the American College of Gastroenterology Annual Scientific Meeting from October 9-14 in Nashville, Tennessee. The presentations will cover VOQUEZNA's efficacy in Non-Erosive GERD across BMI subgroups, real-world patient characteristics, and a cost-effectiveness analysis compared to proton pump inhibitors in Erosive Esophagitis. VOQUEZNA is a potassium-competitive acid blocker used to treat Erosive Esophagitis and associated heartburn.